Business
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a license and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody from Simcere, for the treatment of inflammatory bowel disease (IBD).
About this update from Simcere Pharmaceutical Group Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. ","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million ","length":139,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":438,"olType":false},{"type":"text","content":"SHANGHAI, Jan. 27, 2026 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a license and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody from Simcere, for the treatment of inflammatory bowel disease (IBD).","length":325,"tagName":"p"},{"type":"image","alt":"Cooperation of Simcere and Boehringer Ingelheim","displaySize":"","headline":null,"caption":"Cooperation of Simcere and Boehringer Ingelheim","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":170,"url":"https://media.zenfs.com/en/prnewswire.com/06bfc937ea8b56481997f1f833526dfd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k9Y84GLwr6cac.ah37bG7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/06bfc937ea8b56481997f1f833526dfd","width":400,"height":170}},"href":"https://mma.prnewswire.com/media/2870432/17694775722810.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Globally, it is estimated that more than three million people are affected by IBD, a lifelong, progressive condition leading to frequent hospitalization and surgeries, significantly impacting patients' quality of life. Current medical options cannot fully prevent or reverse these complications, leaving a clear unmet need. Through this partnership, Boehringer and Simcere aim to advance an innovative approach to potentially redefine treatment possibilities and improve outcomes for patients worldwide.","length":507,"tagName":"p"},{"type":"text","content":"SIM0709 is a long-acting ...